Articles > Business magazines > Trade magazines > BIOTECH Patent News articles > October-December 2002 > Tuesday, October 1

Article: Cyclis completes cancer licensing agreement with Beth Israel.(Cyclis Pharmaceuticals Inc., Beth Israel Deaconess Medical Center)

Article from:
BIOTECH Patent News
Article date:
October 1, 2002
Copyright

Cyclis Pharmaceuticals, Inc. (Norwood, MA), a privately held biopharmaceutical company developing novel cancer therapeutics, has licensed exclusive worldwide rights to broad technology from the Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute. The licensed technology significantly expands the company's Activated Checkpoint Therapy platform. The Activated Checkpoint Therapy platform is a novel approach to cancer treatment based on the restoration and activation of cellular checkpoints, which are generally defective in cancer cells.

The licensed intellectual property includes two patents that broadly protect the concept of checkpoint ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: ArQule Discovers Second Activated Checkpoint ...

  
  Business Wire; 
  February 28, 2006 ;  
  
  
 
  700+ words
... ... generated through the Company's ARQ-550RP Activated Checkpoint Therapy(SM) (ACT) program, under its agreement ... development of cancer. ArQule's innovative Activated Checkpoint Therapy(SM) (ACT) platform is generating products ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Cyclis Pharmaceuticals Completes $5 Million Initial Financing to ...

  
  PR Newswire; 
  July 17, 2002 ;  
  
  
 
  700+ words
... ... activation of cellular checkpoints. The Company's Activated Checkpoint Therapy ("ACT") approach uses small molecule drugs ... represents a significant endorsement of our Activated Checkpoint Therapy approach-an approach that the Company believes ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Cyclis Completes Licensing Agreement with Beth Israel Deaconess ...

  
  PR Newswire; 
  October 9, 2002 ;  
  
  
 
  700+ words
... ... technology significantly expands the Company's Activated Checkpoint Therapy ("ACT") platform. The ACT platform is ... checkpoints. The Company's unique approach, Activated Checkpoint Therapy ("ACT"), is an innovative form of targeted ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ArQule Presents Preliminary Interim Phase 1 Data for ARQ 501 and ...

  
  PR Newswire; 
  September 29, 2004 ;  
  
  
 
  700+ words
... ... advanced compound developed using its proprietary Activated Checkpoint Therapy(SM) (ACT(SM)) platform. Additional ... cancer therapeutics based on its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform. ACT(SM ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ArQule Cancer Research Makes Top Ten List In Peer-Reviewed Cell ...

  
  PR Newswire; 
  November 20, 2003 ;  
  
  
 
  700+ words
... ... the scientific community of our innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform, ArQule's ... inflammation. The Company is applying its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform and its small ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ArQule Reports Third Quarter 2003 Financial Results; Conference ...

  
  PR Newswire; 
  October 23, 2003 ;  
  
  
 
  700+ words
... ... gained a novel anti-cancer biology approach, Activated Checkpoint Therapy(SM) (ACT(SM)); a lead clinical candidate ... Institute. Dr. Li, the co- inventor of Activated Checkpoint Therapy(SM), is responsible for ArQule's discovery ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ArQule Announces Enrollment of First Patient in Phase 1b/2 ...

  
  PR Newswire; 
  January 26, 2005 ;  
  
  
 
  700+ words
... ... advanced compound developed using its proprietary Activated Checkpoint Therapy(SM) (ACT(SM)) platform. Two phase ... cancer therapeutics based on its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform. ACT(SM ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met ...

  
  Business Wire; 
  March 14, 2007 ;  
  
  
 
  700+ words
... ... and is the lead product from the Company's Activated Checkpoint Therapy (ACT) platform. The American Association ... platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy([R]) (ACT). The Cancer Survival Protein ... 







   
 






   



















 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives